Halozyme partners with Incyte on ENHANZE subcutaneous formulation for INCA033989 antibody
HALO•Halozyme and Incyte sign global collaboration
Halozyme entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using ENHANZE technology.
Deal terms include upfront, milestones and royalties
Terms include an upfront payment, milestone payments, royalties on net sales, and an option for Incyte to add up to two more targets.
Program targets mutant calreticulin-expressing myeloproliferative neoplasms
The work targets mutant calreticulin-expressing myeloproliferative neoplasms, aiming for more convenient dosing and delivery versus current development plans.
